Related Experiment Video
Updated: Jun 27, 2026
04:47
Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
Infliximab for treating axial spondylarthropathy in everyday practice
Isabelle Griffoul1, Bruno Giraudeau, Denis Mulleman
1CHRU de Tours, Service de Rhumatologie, Avenue de la République, 37044 Tours cedex 9, France.
Joint Bone Spine
|December 10, 2008
Summary
Infliximab showed lower effectiveness in real-world ankylosing spondylitis (AS) treatment than in trials. Patient selection for TNF antagonists needs stricter adherence to criteria for optimal outcomes.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Tumor Necrosis Factor (TNF) antagonists have transformed ankylosing spondylitis (AS) treatment.
- Real-world effectiveness of infliximab in AS requires evaluation beyond controlled trials.
Purpose of the Study:
- Assess infliximab's effectiveness in axial spondyloarthropathies in routine practice.
- Identify predictors of treatment response and evaluate adherence to diagnostic and treatment guidelines.
Main Methods:
- Retrospective review of 86 patients with axial spondyloarthropathy treated with infliximab (2001-2003).
- Recorded disease activity, motion limitation, lab tests, and 6-week response rates.
Main Results:
- 37% of patients responded to infliximab; uveitis and elevated C-reactive protein predicted response.
- Only 53% met modified New York criteria, and 23% met ASAS criteria for TNF antagonist initiation.
Conclusions:
- Infliximab's real-world effectiveness was lower than anticipated from clinical trials.
- Suboptimal patient selection based on criteria may impact outcomes; stricter criteria are recommended for TNF antagonist therapy in spondyloarthropathies.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...